Eli Lil­ly and So­sei en­ter in­to di­a­betes and meta­bol­ic dis­ease deal, go­ing af­ter GPCR

Japan’s So­sei Hep­tares is part­ner­ing up with an­oth­er big-name play­er: Eli Lil­ly.

Un­der the agree­ment, Eli Lil­ly will pay So­sei $37 mil­lion up­front with a pos­si­bil­i­ty of up to $694 mil­lion for de­vel­op­ment and com­mer­cial mile­stones and then tiered roy­al­ties on glob­al sales. The pair will aim to de­sign small mol­e­cule drugs go­ing af­ter G pro­tein-cou­pled re­cep­tor (GPCR) tar­gets to treat di­a­betes and oth­er meta­bol­ic dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.